Guardian Pharmacy Services (GRDN) Competitors

Guardian Pharmacy Services logo
$47.09 +0.42 (+0.90%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$46.98 -0.11 (-0.22%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRDN vs. TEM, FMS, DVA, HNGE, and CHE

Should you buy Guardian Pharmacy Services stock or one of its competitors? Guardian Pharmacy Services's main competitors and comparable companies include Tempus AI (TEM), Fresenius Medical Care AG & Co. KGaA (FMS), DaVita (DVA), Hinge Health (HNGE), and Chemed (CHE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Guardian Pharmacy Services compare to Tempus AI?

Guardian Pharmacy Services (NYSE:GRDN) and Tempus AI (NASDAQ:TEM) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

24.2% of Tempus AI shares are owned by institutional investors. 33.0% of Guardian Pharmacy Services shares are owned by insiders. Comparatively, 24.3% of Tempus AI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Tempus AI had 30 more articles in the media than Guardian Pharmacy Services. MarketBeat recorded 33 mentions for Tempus AI and 3 mentions for Guardian Pharmacy Services. Guardian Pharmacy Services' average media sentiment score of 0.31 beat Tempus AI's score of 0.30 indicating that Guardian Pharmacy Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Guardian Pharmacy Services
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tempus AI
13 Very Positive mention(s)
5 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Guardian Pharmacy Services has a net margin of 5.13% compared to Tempus AI's net margin of -12.54%. Guardian Pharmacy Services' return on equity of 30.29% beat Tempus AI's return on equity.

Company Net Margins Return on Equity Return on Assets
Guardian Pharmacy Services5.13% 30.29% 16.86%
Tempus AI -12.54%-47.00%-9.44%

Guardian Pharmacy Services has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardian Pharmacy Services$1.45B2.06$49.22M$1.1740.25
Tempus AI$1.27B7.74-$245.03M-$1.06N/A

Guardian Pharmacy Services presently has a consensus price target of $45.57, suggesting a potential downside of 3.22%. Tempus AI has a consensus price target of $79.37, suggesting a potential upside of 47.04%. Given Tempus AI's higher probable upside, analysts plainly believe Tempus AI is more favorable than Guardian Pharmacy Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardian Pharmacy Services
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Tempus AI
1 Sell rating(s)
10 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.45

Guardian Pharmacy Services has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, Tempus AI has a beta of 3.61, suggesting that its stock price is 261% more volatile than the broader market.

Summary

Guardian Pharmacy Services beats Tempus AI on 10 of the 16 factors compared between the two stocks.

How does Guardian Pharmacy Services compare to Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Guardian Pharmacy Services (NYSE:GRDN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Fresenius Medical Care AG & Co. KGaA has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Guardian Pharmacy Services has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market.

Guardian Pharmacy Services has a net margin of 5.13% compared to Fresenius Medical Care AG & Co. KGaA's net margin of 4.23%. Guardian Pharmacy Services' return on equity of 30.29% beat Fresenius Medical Care AG & Co. KGaA's return on equity.

Company Net Margins Return on Equity Return on Assets
Fresenius Medical Care AG & Co. KGaA4.23% 9.08% 4.04%
Guardian Pharmacy Services 5.13%30.29%16.86%

Fresenius Medical Care AG & Co. KGaA presently has a consensus target price of $23.43, suggesting a potential upside of 14.74%. Guardian Pharmacy Services has a consensus target price of $45.57, suggesting a potential downside of 3.22%. Given Fresenius Medical Care AG & Co. KGaA's higher possible upside, equities analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Guardian Pharmacy Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fresenius Medical Care AG & Co. KGaA
5 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.58
Guardian Pharmacy Services
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Guardian Pharmacy Services. Fresenius Medical Care AG & Co. KGaA is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$22.20B0.49$1.11B$1.7311.80
Guardian Pharmacy Services$1.45B2.06$49.22M$1.1740.25

8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 33.0% of Guardian Pharmacy Services shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Guardian Pharmacy Services had 1 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 3 mentions for Guardian Pharmacy Services and 2 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.42 beat Guardian Pharmacy Services' score of 0.31 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fresenius Medical Care AG & Co. KGaA
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Guardian Pharmacy Services
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Guardian Pharmacy Services beats Fresenius Medical Care AG & Co. KGaA on 9 of the 16 factors compared between the two stocks.

How does Guardian Pharmacy Services compare to DaVita?

DaVita (NYSE:DVA) and Guardian Pharmacy Services (NYSE:GRDN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

DaVita has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Guardian Pharmacy Services has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market.

In the previous week, DaVita had 3 more articles in the media than Guardian Pharmacy Services. MarketBeat recorded 6 mentions for DaVita and 3 mentions for Guardian Pharmacy Services. DaVita's average media sentiment score of 0.47 beat Guardian Pharmacy Services' score of 0.31 indicating that DaVita is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DaVita
0 Very Positive mention(s)
5 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Guardian Pharmacy Services
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

DaVita currently has a consensus price target of $235.86, indicating a potential upside of 46.43%. Guardian Pharmacy Services has a consensus price target of $45.57, indicating a potential downside of 3.22%. Given DaVita's higher possible upside, equities research analysts plainly believe DaVita is more favorable than Guardian Pharmacy Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DaVita
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57
Guardian Pharmacy Services
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

90.1% of DaVita shares are held by institutional investors. 1.9% of DaVita shares are held by insiders. Comparatively, 33.0% of Guardian Pharmacy Services shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

DaVita has higher revenue and earnings than Guardian Pharmacy Services. DaVita is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$13.64B0.74$746.80M$13.5811.86
Guardian Pharmacy Services$1.45B2.06$49.22M$1.1740.25

DaVita has a net margin of 6.49% compared to Guardian Pharmacy Services' net margin of 5.13%. Guardian Pharmacy Services' return on equity of 30.29% beat DaVita's return on equity.

Company Net Margins Return on Equity Return on Assets
DaVita6.49% -225.93% 5.42%
Guardian Pharmacy Services 5.13%30.29%16.86%

Summary

DaVita beats Guardian Pharmacy Services on 9 of the 16 factors compared between the two stocks.

How does Guardian Pharmacy Services compare to Hinge Health?

Guardian Pharmacy Services (NYSE:GRDN) and Hinge Health (NYSE:HNGE) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Guardian Pharmacy Services has higher revenue and earnings than Hinge Health. Guardian Pharmacy Services is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardian Pharmacy Services$1.45B2.06$49.22M$1.1740.25
Hinge Health$587.86M14.61-$528.26M$1.9653.90

Hinge Health has a net margin of 21.02% compared to Guardian Pharmacy Services' net margin of 5.13%. Hinge Health's return on equity of 66.96% beat Guardian Pharmacy Services' return on equity.

Company Net Margins Return on Equity Return on Assets
Guardian Pharmacy Services5.13% 30.29% 16.86%
Hinge Health 21.02%66.96%19.70%

In the previous week, Hinge Health had 5 more articles in the media than Guardian Pharmacy Services. MarketBeat recorded 8 mentions for Hinge Health and 3 mentions for Guardian Pharmacy Services. Hinge Health's average media sentiment score of 0.97 beat Guardian Pharmacy Services' score of 0.31 indicating that Hinge Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Guardian Pharmacy Services
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hinge Health
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Guardian Pharmacy Services has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, Hinge Health has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Guardian Pharmacy Services presently has a consensus price target of $45.57, indicating a potential downside of 3.22%. Hinge Health has a consensus price target of $118.93, indicating a potential upside of 12.57%. Given Hinge Health's stronger consensus rating and higher probable upside, analysts plainly believe Hinge Health is more favorable than Guardian Pharmacy Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardian Pharmacy Services
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Hinge Health
0 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
3.00

Summary

Hinge Health beats Guardian Pharmacy Services on 13 of the 15 factors compared between the two stocks.

How does Guardian Pharmacy Services compare to Chemed?

Guardian Pharmacy Services (NYSE:GRDN) and Chemed (NYSE:CHE) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

95.9% of Chemed shares are owned by institutional investors. 33.0% of Guardian Pharmacy Services shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Guardian Pharmacy Services currently has a consensus target price of $45.57, indicating a potential downside of 3.22%. Chemed has a consensus target price of $603.00, indicating a potential upside of 9.79%. Given Chemed's higher possible upside, analysts clearly believe Chemed is more favorable than Guardian Pharmacy Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardian Pharmacy Services
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Chemed
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

Chemed has a net margin of 10.61% compared to Guardian Pharmacy Services' net margin of 5.13%. Chemed's return on equity of 35.18% beat Guardian Pharmacy Services' return on equity.

Company Net Margins Return on Equity Return on Assets
Guardian Pharmacy Services5.13% 30.29% 16.86%
Chemed 10.61%35.18%19.43%

Guardian Pharmacy Services has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market. Comparatively, Chemed has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

In the previous week, Guardian Pharmacy Services and Guardian Pharmacy Services both had 3 articles in the media. Chemed's average media sentiment score of 1.16 beat Guardian Pharmacy Services' score of 0.31 indicating that Chemed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Guardian Pharmacy Services
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Chemed
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Chemed has higher revenue and earnings than Guardian Pharmacy Services. Chemed is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardian Pharmacy Services$1.45B2.06$49.22M$1.1740.25
Chemed$2.53B2.83$265.24M$20.9026.28

Summary

Chemed beats Guardian Pharmacy Services on 11 of the 15 factors compared between the two stocks.

Get Guardian Pharmacy Services News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRDN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRDN vs. The Competition

MetricGuardian Pharmacy ServicesHealthcare Providers & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$2.97B$9.75B$7.44B$20.37B
Dividend YieldN/A2.58%2.51%3.97%
P/E Ratio40.2532.3132.5627.91
Price / Sales2.051.877.713.41
Price / Cash37.2721.6320.2514.62
Price / Book10.653.574.343.40
Net Income$49.22M$329.93M$3.51B$1.07B
7 Day Performance-4.99%-7.06%-8.07%-7.13%
1 Month Performance18.57%-7.73%-10.29%-7.56%
1 Year Performance65.62%10.82%-4.70%0.53%

Guardian Pharmacy Services Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRDN
Guardian Pharmacy Services
1.6632 of 5 stars
$47.09
+0.9%
$45.57
-3.2%
+65.6%$2.97B$1.46B40.253,600
TEM
Tempus AI
3.1193 of 5 stars
$63.62
+0.3%
$79.37
+24.8%
-23.2%$11.57B$1.27BN/A3,800
FMS
Fresenius Medical Care AG & Co. KGaA
3.9729 of 5 stars
$20.97
-3.3%
$23.43
+11.7%
-12.9%$11.54B$22.20B8.151,488
DVA
DaVita
4.2683 of 5 stars
$161.66
-6.6%
$235.86
+45.9%
+34.1%$10.88B$14.17B11.9078,000
HNGE
Hinge Health
3.1022 of 5 stars
$114.52
+0.1%
$118.93
+3.9%
+129.5%$9.30B$587.86M62.181,437

Related Companies and Tools


This page (NYSE:GRDN) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners